Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
33.88(c) 33.01(c) 33.37(c) 33.03(c) 36.39(c) Last
594 449 464 915 369 508 347 832 1 681 405 Volume
+4.60% -2.57% +1.09% -1.02% +10.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 39,3 M - -
Net income 2021 -300 M - -
Net cash position 2021 555 M - -
P/E ratio 2021 -8,49x
Yield 2021 -
Sales 2022 123 M - -
Net income 2022 -268 M - -
Net cash position 2022 511 M - -
P/E ratio 2022 -9,78x
Yield 2022 -
Capitalization 2 598 M 2 598 M -
EV / Sales 2021 52,0x
EV / Sales 2022 17,0x
Nbr of Employees 236
Free-Float 63,2%
More Financials
Company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. It is focused on creating, developing and... 
Sector
Pharmaceuticals
Calendar
09/27 | 04:40pmPresentation
More about the company
Ratings of Arcus Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about ARCUS BIOSCIENCES, INC.
09/17ARCUS BIOSCIENCES : Thinking about buying stock in Corvus Pharmaceuticals, AbCel..
PR
09/09ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
09/01ARCUS BIOSCIENCES : to Participate at Upcoming Investor Conferences
BU
08/24ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
08/11ARCUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/11Arcus Biosciences, Inc. Announces Board Changes
CI
08/10ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
08/06ARCUS BIOSCIENCES : SVB Leerink Adjusts Price Target on Arcus Biosciences to $68..
MT
08/05ARCUS BIOSCIENCES : Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q2 Revenue $..
MT
08/05ARCUS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
08/05ARCUS BIOSCIENCES : Reports Second Quarter 2021 Financial Results and Provides O..
BU
08/05ARCUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Change ..
AQ
08/05Arcus Biosciences, Inc. Appoints Nicole Lambert to the Board as Class II Dire..
CI
08/05Arcus Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended..
CI
08/04ARCUS BIOSCIENCES : to Participate at the 2021 Wedbush PacGrow Virtual Healthcar..
BU
More news
News in other languages on ARCUS BIOSCIENCES, INC.
2020EN DIRECT DES MARCHES : ADP, Nexity, Lagardère, bioMérieux, Virbac, Novacyt, ..
2020Le déconfinement comme remède économique
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | RCUS | US03969F1093 | MarketScreener
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 36,39 $
Average target price 53,90 $
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.40.18%2 598
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604